Prudential PLC Buys 14,820 Shares of Insulet Corporation $PODD

Prudential PLC grew its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 287.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 19,977 shares of the medical instruments supplier’s stock after purchasing an additional 14,820 shares during the quarter. Prudential PLC’s holdings in Insulet were worth $5,678,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Westfield Capital Management Co. LP boosted its holdings in shares of Insulet by 91.9% during the 4th quarter. Westfield Capital Management Co. LP now owns 386,468 shares of the medical instruments supplier’s stock worth $109,850,000 after buying an additional 185,081 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Insulet by 17.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 19,071 shares of the medical instruments supplier’s stock worth $5,421,000 after buying an additional 2,833 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Insulet by 11.5% during the 4th quarter. TD Asset Management Inc now owns 44,119 shares of the medical instruments supplier’s stock worth $12,540,000 after buying an additional 4,551 shares in the last quarter. Cibc World Market Inc. bought a new position in shares of Insulet during the 4th quarter worth approximately $1,502,000. Finally, Sivia Capital Partners LLC bought a new position in shares of Insulet during the 4th quarter worth approximately $266,000.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. Truist Financial cut their price target on Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. BTIG Research cut their price target on Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a report on Tuesday, May 26th. Evercore cut their price target on Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. TD Cowen cut their price target on Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a report on Monday, June 1st. Finally, Barclays cut their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.04.

Insider Buying and Selling

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.36% of the company’s stock.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $153.22 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The stock’s 50 day moving average is $175.73 and its 200-day moving average is $238.90. The firm has a market capitalization of $10.61 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 1.21 and a beta of 1.13.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same period in the prior year, the firm earned $1.02 earnings per share. Insulet’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts forecast that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.